Eterna Therapeutics (NASDAQ:ERNA) Shares Down 8.1% – What’s Next?

Eterna Therapeutics Inc. (NASDAQ:ERNA) was down 8.1% on Tuesday . The company traded as low as $0.86 and last traded at $0.91. Approximately 105,356 shares were traded during trading, an increase of 615% from the average daily volume of 14,735 shares. The stock had previously closed at $0.99.

Eterna Therapeutics Stock Performance

The stock has a 50 day simple moving average of $1.37 and a two-hundred day simple moving average of $1.74. The firm has a market cap of $5.14 million, a PE ratio of -0.21 and a beta of 4.39.

Eterna Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($1.02) earnings per share for the quarter. The company had revenue of $0.05 million for the quarter. Eterna Therapeutics had a negative net margin of 14,765.43% and a negative return on equity of 1,466.71%.

Institutional Investors Weigh In On Eterna Therapeutics

A hedge fund recently bought a new stake in Eterna Therapeutics stock. Avidian Wealth Solutions LLC bought a new stake in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 14,798 shares of the company’s stock, valued at approximately $36,000. Avidian Wealth Solutions LLC owned 0.27% of Eterna Therapeutics as of its most recent SEC filing. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

About Eterna Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.